Day 2 Program

Rapid Fire 6

Day 2: December 10, 2025

1:00 PM–2:00 PM CST

Stars at Night 1-2

Session Details

Oral presentations of high impact abstracts.
The text of the abstracts will be posted on Monday, November 24.

Moderator

Aditya Bardia, University of California Los Angeles, Los Angeles, TX

RF6-01

Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with high-risk human epidermal growth factor receptor 2-positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05

Sibylle Loibl, GBG Neu-Isenburg and Goethe University, Neu-Isenburg, Germany

RF6-02

DESTINY-Breast11 (DB-11) safety: neoadjuvant trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + anthracycline followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC)

Giuseppe Curigliano, Division of Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS & Department of Oncology and Hematology-Oncology, University of Milano, Milano, Italy

RF6-03

Efficacy and safety of DP303c versus T-DM1 in HER2-positive advanced breast cancer: Interim analysis of a randomized, open-label, phase 3 trial​

Hui-Ping Li, Beijing Cancer Hospital, Beijing, China

RF6-04

Associations Between Cardiac Radiation Dose Volume Metrics and Cardiac Specific Health Related Quality of Life for Patients with Breast Cancer Randomized to Proton versus Photon Radiation on the RadComp Trial

Jean L Wright, University of North Carolina, Chapel Hill, NC

RF6-05

Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) vs chemotherapy in patients with previously untreated advanced triple-negative breast cancer (TNBC) who are not candidates for PD-(L)1 inhibitors in the phase 3 ASCENT-03 study

Kevin Punie, Oncology Center Antwerp, Ziekenhuis aan de Stroom, Antwerp, Belgium

RF6-06

Patient-reported outcomes (PROs) in DESTINY-Breast11: neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + anthracycline followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC)

Shanu Modi, Department of Medicine, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY

RF6-07

Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with HER2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): patient-reported outcomes (PROs) from the DESTINY-Breast09 study

Mothaffar Rimawi, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX

RF6-08

Patient Reported Outcomes: Bridging the Gap Between Reporting and Reality

Maryam Lustberg, Yale School of Medicine, New Haven, CT

RF6-09

Fixing a Toxic Friendship: The Patient Experience with ADCs in Metastatic Breast Cancer

Amy Beumer, Patient Centered Dosing Initiative, Denver, CO